Alnylam Pharmaceuticals, Inc.
Hepatitis B virus (HBV) iRNA compositions and methods of use thereof

Abstract:

The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the hepatitis B virus (HBV) genome, and methods of using such RNAi agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HBV infection and/or HBV-associated disorder, e.g., chronic hepatitis B infection.